Ayman J. Oweida
Has grant
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Ayman J. Oweida is an assistant professor at Université de Sherbrooke in Canada. His research primarily focuses on the interplay between immunotherapy and radiotherapy in solid tumors, particularly in head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer. He has published articles examining the roles of various signaling pathways and immune cell interactions in the response to radiation therapy.
Recent Grants
Grant: Close
Targeting immunosuppressive chemokines for enhanced response to radiotherapy in squamous cell cancers
Open Date: 2021-09-01
Close Date: 2023-08-31
Grant: Close
Radiotherapy for stimulation of anti-tumor immunity
Open Date: 2021-03-23
Close Date:
Grant: Close
Anti-Tumor Immunity by Radiotherapy
Open Date: 2021-02-01
Close Date: 2026-01-31
Grant: Close
Development of an immune imaging method to accurately determine the immune status of tumors
Open Date: 2020-04-01
Close Date: 2021-03-31
Grant: Close
Compréhension des mécanismes impliqués dans la réponse aux traitements anti-cancéreux combinant immunothérapie et radiothérapie
Open Date: 2020-04-01
Close Date: 2024-03-31
Articles (10)
Toll-like receptors (TLRs) are indispensable for the activation, maintenance and halting of immune responses. TLRs can mediate inflammation by recognizing molecular patterns in microbes (pathogen-associated molecular patterns: PAMPs) and endogenous ligands (danger-associated molecular patterns: DAMPs) released by injured or dead cells. For this reason, TLR ligands have attracted much attention in recent years in many cancer vaccines, alone or in combination with immunotherapy, chemotherapy and radiotherapy (RT). TLRs have been shown to play controversial roles in cancer, depending on various factors that can mediate tumor progression or apoptosis. Several TLR agonists have reached clinical trials and are being evaluated in combination with standard of care therapies, including RT. Despite their prolific and central role in mediating immune responses, the role of TLRs in cancer, particularly in response to radiation, remains poorly understood. Radiation is recognized as either a direct stimulant of TLR pathways, or indirectly through the damage it causes to target cells that subsequently activate TLRs. These effects can mediate pro-tumoral and anti-tumoral effects depending on various factors such as radiation dose and fractionation, as well as host genomic features. In this review, we examine how TLR signaling affects tumor response to RT, and we provide a framework for the design of TLR-based therapies with RT.
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2020
Year:
2020
Collaborators (3)
Brisa Peña
Assistant Professor
University of Denver
Adam Mueller
Assistant Professor
University of Pittsburgh
Jennifer Boer
MONASH UNIVERSITY
Make your next move.
Prepare your application
Review drafts before you send them.